Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GE Healthcare

The dark side of direct-to-consumer genetic tests

Direct-to-consumer testing is an affordable way to better understand your DNA, but is this a leap forward in innovation or another layer clouding an already complex market? From anxious patients...

Blue Latitude Health

- PMLiVE

Roche’s Tecentriq misses survival mark in frontline NSCLC

Keytruda proving hard to beat

- PMLiVE

Labour party divided on Brexit ‘People’s Vote’

Growing support for second referendum being resisted by party leaders

- PMLiVE

J&J files ‘breakthrough’ bladder cancer drug in US

Needed as most patients don't respond to checkpoint inhibitors

- PMLiVE

AZ nabs US approval for new leukaemia drug Lumoxiti

Adds to firm's growing oncology franchise

Roche Basel Switzerland

Dismay as NICE rejects Roche’s MS drug Ocrevus

Treatment deemed too costly to treat primary progressive MS

- PMLiVE

NICE turns down Opdivo for adjuvant melanoma therapy

BMS drug currently only licensed treatment in this setting

- PMLiVE

Roche highlights Hemlibra data as key FDA date approaches

Expanded use would see revenues take off

Roche Basel Switzerland

Affimed rockets on $5bn-plus Roche immuno-oncology deal

Deal is latest in series of big pharma investments in cancer immunotherapies

- PMLiVE

Novartis wins key adjuvant Taf/Mek approval in Europe

Ex-GSK duo on course for first blockbuster year

- PMLiVE

Roche Diagnostics’ chief heads for the exit

No surprise if Diggelmann resurfaces at diagnostics start-up or rival

- PMLiVE

Roche’s Alecensa backed by China’s National Drug Administration

Approved to treat ALK-positive lung cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links